Investigation of rate + extent of excretion of radioactivity in urine +faeces after oral administration of [14C]AZD2066

Study identifier:D0475C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open label, Single dose, Phase I study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics following Oral administration of [14C]AZD2066 to Healthy Male Subjects

Medical condition

Pain

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2066

Sex

Male

Actual Enrollment

Study type

Interventional

Age

35 Years - 50 Years

Date

Study Start Date: 01 Jan 2009

Primary Completion Date: -

Study Completion Date: 01 Feb 2009

Study design

Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

CHESHIRE, United Kingdom

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1639&filename=CSR-D0475C00008.pdf
Download
CSR-D0475C00008.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Emeline Ramos

AstraZeneca R&D, CPU Alderley Park, UK